Jefferies raises Eli Lilly price target to $1,610 from $1,440
Jefferies raised its price target for Eli Lilly to $1,610 from $1,440.
Related stories
Goldman Sachs Raises Voting Stake in AUTO1
M impact | EQUITY | Oct 30, 2026, 05:03 PM UTC
UBS Says Alnylam Fundamentals Remain Strong Despite Lower-End Guidance Expectations
UBS says Alnylam Pharmaceuticals' fundamentals remain strong despite expectations for guidance at the lower end.
M impact | EQUITY | Oct 30, 2026, 05:03 PM UTC
Morgan Stanley Raises Its Voting Stake in Norma Group
Morgan Stanley increased its voting-rights stake in Norma Group.
M impact | EQUITY | Oct 30, 2026, 05:01 PM UTC
US session market picture: S&P 500 -1.81%, Nasdaq 100 -3.51%; EUR/USD -0.2%, WTI +2.88%, INTC leads volume
US session market picture. US index futures: S and P futures is down 1.81 percent, Nasdaq futures is down 3.51 percent, Dow futures is down 0.99 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 05:01 PM UTC
U.S. Stocks Extend Fall; Nasdaq Down 3.00%
M impact | EQUITY | Oct 30, 2026, 04:51 PM UTC
UBS Sees Eli Lilly Sustaining Obesity Growth
UBS said Eli Lilly's strong results and higher guidance support continued obesity growth.
M impact | EQUITY | Oct 30, 2026, 04:50 PM UTC